Valneva SE (EPA:VLA)

Market Cap	735.26M
Revenue (ttm)	179.91M
Net Income (ttm)	-102.16M
Shares Out	172.76M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,871
Average Volume	730,430
Open	4.290
Previous Close	4.256
Day's Range	4.266 - 4.430
52-Week Range	2.050 - 5.415
Beta	1.19
RSI	67.70
Earnings Date	Mar 1, 2026

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 713
• Stock Exchange: Euronext Paris
• Ticker Symbol: VLA

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.